GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 1,653 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,653 shares of GeneDx stock in a transaction that occurred on Thursday, January 29th. The stock was sold at an average price of $94.00, for a total transaction of $155,382.00. Following the transaction, the chief executive officer directly owned 16,458 shares in the company, valued at $1,547,052. The trade was a 9.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The stock was sold at an average price of $143.89, for a total value of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total value of $579,619.92.

GeneDx Price Performance

NASDAQ WGS opened at $99.01 on Tuesday. The business has a 50 day simple moving average of $132.47 and a 200 day simple moving average of $125.01. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.59 and a current ratio of 2.71. GeneDx Holdings Corp. has a 52-week low of $55.17 and a 52-week high of $170.87. The stock has a market cap of $2.86 billion, a price-to-earnings ratio of 1,100.11 and a beta of 2.01.

Analyst Ratings Changes

Several brokerages have commented on WGS. BTIG Research boosted their price target on shares of GeneDx from $165.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Wells Fargo & Company set a $155.00 target price on shares of GeneDx and gave the stock an “equal weight” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Canaccord Genuity Group increased their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, Guggenheim reissued a “buy” rating and set a $170.00 target price (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $138.13.

Hedge Funds Weigh In On GeneDx

A number of institutional investors and hedge funds have recently bought and sold shares of the company. ARK Investment Management LLC bought a new stake in shares of GeneDx during the third quarter worth about $48,157,000. William Blair Investment Management LLC grew its holdings in GeneDx by 37.2% during the 2nd quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after acquiring an additional 442,414 shares during the last quarter. Jennison Associates LLC increased its position in GeneDx by 6,163.1% in the 2nd quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock valued at $36,730,000 after acquiring an additional 391,543 shares during the period. Westfield Capital Management Co. LP increased its position in GeneDx by 164.8% in the 2nd quarter. Westfield Capital Management Co. LP now owns 589,188 shares of the company’s stock valued at $54,388,000 after acquiring an additional 366,711 shares during the period. Finally, Franklin Resources Inc. raised its stake in shares of GeneDx by 101.9% during the third quarter. Franklin Resources Inc. now owns 681,381 shares of the company’s stock valued at $73,412,000 after acquiring an additional 343,954 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.